Insomnia and inflammation in phase 1 of the clinical antipsychotic trials of intervention effectiveness study

Research output: Contribution to journalArticlepeer-review

Abstract

Insomnia and inflammation are both common in schizophrenia. In the general population, insomnia is associated with inflammation. In n=519 subjects from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, terminal insomnia was investigated as an indicator of inflammation using non-parametric ANCOVA. After controlling for potential confounders, insomnia was significantly associated with higher blood IL-6 (F=4.12, p=0.007) and leptin (F=9.67, p<0.001) with large effect sizes (d=1.03 and d=0.79, respectively). Findings suggest that the assessment of insomnia is relevant to studies of inflammation in schizophrenia, and germane to trials of adjunctive hypnotics and anti-inflammatory agents in these patients.

Original languageEnglish (US)
Pages (from-to)114195
JournalPsychiatry Research
Volume305
DOIs
StateE-pub ahead of print - Aug 29 2021

Fingerprint

Dive into the research topics of 'Insomnia and inflammation in phase 1 of the clinical antipsychotic trials of intervention effectiveness study'. Together they form a unique fingerprint.

Cite this